Physiologically based pharmacokinetic modeling of drug-drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy

• Main Authors: Shakir Atoyebi (Author), Maiara Camotti Montanha (Author), Ritah Nakijoba (Author), Catherine Orrell (Author), Henry Mugerwa (Author), Marco Siccardi (Author), Paolo Denti (Author), Catriona Waitt (Author)
• Format: Book
• Published: Wiley, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Ritonavir‐boosted atazanavir (ATV/r) and rifampicin are mainstays of second‐line antiretroviral and multiple anti‐TB regimens, respectively. Rifampicin induces CYP3A4, a major enzyme involved in atazanavir metabolism, causing a drug-drug interaction (DDI) which might be exaggerated in pregn...